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ORIGINAL ARTICLE
Cancer is a major public health issue, due to
both the suffering it causes and the financial bur-
den that it places on patients and their families.
In England, currently about one person in three
develops a cancer in their lifetime, and cancer
causes about one in four deaths.1 In Taiwan,
claims for the reimbursement of medical ex-
penses for the diagnosis and treatment of cancer
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Insurance (NHI) is important for helping policy makers to plan under scarce healthcare resources. This
study attempts to estimate lifetime health expenditure for patients with 17 types of major cancers.
Methods: A total of 425,294 patients, each of whom was registered in Taiwan during 1990 to 2001 as 
having one of 17 major types of cancers, were included. All of them were followed until the end of 2004.
Monte Carlo simulation was used to extrapolate survival for up to 600 months to derive the life 
expectancy or lifetime survival function after diagnosis for different cancers. The average annual health 
expenditure per case for each cancer type was calculated by using data from the NHI’s reimbursement
database. The lifetime health expenditure per case was estimated by multiplying the monthly survival
probability by the average monthly health expenditure, adjusting for the annual discount rate and the
medical care inflation rate. By incorporating the number of annual incidence cases, the total lifetime
health expenditure can also be estimated.
Results: Of the 17 cancers studied, it was found that leukemia had the highest average annual health 
expenditure per case (207,000 TWD) as well as the highest lifetime health expenditure per case (2,404,000
TWD, without discounting adjustment). Breast cancer had the highest total lifetime health expenditure
(5046 million TWD) because of the longer life expectancy and chronic morbidity. Furthermore, colorectal
cancer had the second highest total lifetime health expenditure (4995 million TWD) due to its high incidence.
Conclusion: The proposed method is a feasible way of estimating lifetime health expenditure for cancer
patients even under high censoring rates. This would be helpful for cost-effectiveness assessment of cancer
prevention programs and for policy planning. [J Formos Med Assoc 2008;107(1):54–63]
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on the National Health Insurance (NHI) scheme
were the second highest among major illnesses
and injuries.2 The amount of reimbursement
represents a cause for concern regarding the main-
tenance of the NHI, given the scarce resources and
increase in medical expenses for diagnosing and
treating cancers. Measuring the financial burdens
on patients with cancers could be helpful for
financial planning,3–5 as well as for the long-
term maintenance of the NHI. However, previous
studies have focused mostly on cross-sectional
analysis of the financial burdens of cancer for a
short period of time. The results of these studies
may be useful for policymaking regarding cancer
patients with short-term life expectancy.6 How-
ever, there remains a need to estimate lifetime 
financial burdens,7 which could be useful for the
evaluation of the cost-effectiveness of prevention
programs or new medical treatments.8 The need
for such evaluation is urgent in Taiwan, where all
medical costs related to the diagnosis and manage-
ment of cancer are reimbursed comprehensively
by the NHI.
To estimate the lifetime health expenditure for
cancer patients, the lifetime survival function must
be calculated first. The Monte Carlo method can
be used to estimate the lifetime survival function
beyond the follow-up limit with a certain degree
of accuracy.9 It has been applied to patients who
have serious diseases or conditions that lead to pre-
mature mortality, such as permanent occupational
disabilities,10 transfusion-dependent thalassemia,11
and human immunodeficiency virus infection.12
In addition, the Taiwan NHI reimbursement
database, which covers 97% of the population,13
was used to estimate lifetime health expenditure
for cancer patients. To the best of our knowledge,
no previously published study has estimated life-
time health expenditure for cancer patients in
Taiwan. Therefore, the main objective of the study
reported herein was to estimate the lifetime health
expenditure for cancer patients paid by the NHI.
The estimate was made by analyzing data from
national databases: the National Cancer Registry
database, the National Mortality database, and
the NHI’s reimbursement database.
Methods
Subjects
A total of 425,294 cancer patients were recruited.
The patients were grouped into 17 cancer co-
horts according to the cancer sites, which were
determined based on the code of the International
Classification of Diseases taken from the National
Cancer Registry database for the period from
1990 to 2001. Patients were followed up to the
end of 2004 and the survival status for each can-
cer patient was obtained by linking the patients’
identification (ID) and demographic informa-
tion between the National Cancer Registry data-
base and the National Mortality database. The 17
major cancer sites were as follows: oral cavity, 
nasopharynx, esophagus, stomach, colorectum,
liver, gallbladder and extrahepatic bile duct, pan-
creas, lung, leukemia, skin, breast, cervix uteri,
ovary, prostate, bladder, and kidney and other
urinary organs.
Method for extrapolation of life 
expectancy
After 15 years of follow-up, the lifetime survival
can be obtained for patients with cancers that
yield a short life expectancy, such as liver, lung
and pancreas cancers. However, there are several
cancers that needed projection estimations. For
these cases, we used the method proposed by
Hwang and Wang9 to extrapolate the long-term
or lifetime survival curve beyond the follow-up
period. The approach was to borrow the infor-
mation from the age- and gender-matched refer-
ence population, of which the survival function
can be obtained from the life table of the general
population in Taiwan. The extrapolation process
comprised three phases. First, we chose a reference
person of the same age and gender with a known
hazard function in the life table of the general
population from the National Vital Statistics. The
survival function of the reference person was then
generated according to the Monte Carlo method.
Thus, for the cohorts of each type of cancer, 
we were able to produce an age- and gender-
matched reference population and their survival
curves on the basis of the hazard function for the
general population. Second, the survival func-
tion for the cancer cohorts was divided by that of
the reference population at each time t to pro-
duce a new function, W(t), which was defined as
follows:
W(t) =
S (t | patient population)
S (t | reference population)
Because the cancer cohort has, overall, a lower
survival time than the reference population, the
value of W(t) initially equals 1 at time point
t = 0, then gradually decreases, due to the cancer-
associated excess mortality. Because the value of
W(t) is limited to the range from 0 to 1, linear 
regression for the temporal trend is not applica-
ble. We therefore used the logit transformation
of W(t). The range of values was transformed
from 0 to 1 to that of −∞ to +∞. Furthermore, 
if the cancer-associated excess hazard remains
constant over time, the curve of the logit of W(t)
will converge to a straight line. Then, the logit
transformation of the ratio of survival curves for
both the cancer and the reference populations
was fitted by simple linear regression up to the
end of follow-up. Finally, the estimated regres-
sion line and the survival curve of the reference
population were used to extrapolate the long-
term survival function beyond the follow-up
limit. Hence, life expectancy or the lifetime sur-
vival function (up to 600 months) after diagno-
sis could be estimated. In addition, the monthly
survival probability could also be obtained. The
above approach was demonstrated by computer
simulation in 1999,9 and was proven mathe-
matically, provided that W(t) is a fixed ratio after
a certain period of time.12 The standard error 
of survival estimates was obtained by using a
bootstrap method. The extrapolation process was
implemented by using data that were simulated
by repeated sampling techniques with replace-
ment from a real data set 300 times. In order to
facilitate the above computation, the statistical
package MC-QAS, written in R and S-Plus software,
was used.14
Estimation of lifetime health expenditure
paid by the NHI
The NHI’s reimbursement database for 2001,
which contained data for all outpatients and in-
patients with diagnoses involving the 17 major
cancer sites, was obtained. In general, the NHI
comprehensively reimburses all medical services
for each cancer patient, including various diag-
nostic work-ups and established treatments (e.g.
surgery, radiation therapy, chemotherapy, or man-
agement for various complications). When a can-
cer patient visits a physician, it is the physician’s
responsibility to judge whether the patient’s spe-
cific complaint, and hence the medical services
provided, are related to the diagnosis of his or her
underlying cancer. If so, then the physician can
claim for reimbursement on the category of cancer
diagnosed, using the International Classification
of Diseases (9th revision, clinical modification
[ICD9-CM]), which is automatically registered
into the database. The average annual health ex-
penditure was estimated by using records from
the database, which contained data on 200,000
insured persons, by implementing the procedure
of simple random sampling established by the
Bureau of NHI. The calculation process was as
follows. First, the annual incidence and prevalence
for each cancer site for 2001 were calculated
from the National Cancer Registry and the NHI’s
reimbursement database, respectively. Second, for
each cancer site, we summed up the total med-
ical expenses for each cancer type from the NHI
database in 2001, which was then divided by the
number of prevalence cases to obtain the average
annual health expenditure per case. The average
annual health expenditure per case was divided
by 12 to obtain the average monthly health ex-
penditure per case. This value was then multiplied
by the monthly survival probability, calculated
by using the Monte Carlo method, to obtain the
lifetime health expenditure per case. Furthermore,
the total lifetime health expenditure was esti-
mated by multiplying the lifetime health expen-
diture per case by the number of new cases in
2001. To discount costs in future years, we also
adjusted the lifetime health expenditure, using two
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annual discount rates (3% and 5%) and a medical
care inflation rate (3%). The discount rates of
3% and 5% were recommended by researchers
while conducting the cost-effectiveness analy-
sis15 and 3.625% was the coupon rate of Central
Government Bonds with a maturity period of 
30 years in 2001 in Taiwan.16 Therefore, both 3%
and 5% were chosen to discount. In addition, the
mean of annual change rates from 1995 to 2001
was 3.07 (standard deviation, 1.98), calculated
from the data of the Consumer Price Indices (CPI)
for medical care services.17 Thus, an inflation
rate of 3% on the CPI for medical care services,
as well as 3% and 5% for discount rates, were
chosen for discounting to present values in 2001 or
adjusting to the 2001 New Taiwan Dollar (TWD).
The major process of the method is summarized
as a flowchart in Figure 1.
For comparison, we also estimated the average
annual health expenditure for the general popu-
lation without major illnesses in Taiwan. We ex-
tended the estimation period from a single year
(2001) to 5 years (1999–2003) to reduce a possi-
ble random effect generated by healthy people
who did not use the NHI reimbursement scheme
during the short period of time (i.e. 2001). The
database we used contained data on 200,000 
insured persons, selected by using the procedure 
of simple random sampling established by the
Bureau of NHI. Using the criteria for major ill-
nesses that were provided by the NHI, we identi-
fied 8651 patients with the codes of major illness
National Vital
Statistics
Survival function of
cancer cohorts
Life table of general
population in Taiwan
Monte Carlo method 
Lifetime health expenditure per case for a
type of cancer cohort
Survival function of
reference population
Survival ratio between a specific type of cancer
cohort and reference population at time t
Lifetime survival function and life expectancy
for a type of cancer cohort
National Health Insurance’s
reimbursement database in 2001
Health expenditure for a type of
cancer cohort, divided by number
of prevalence cases in 2001
Average annual health expenditure
per case for a type of cancer cohort,
adjusted for discount rate and
medical care inflation rate 
Logit transformation for lifetime extrapolation 
National Cancer
Registry database
National Mortality
database
17 cancer cohorts 
Figure 1. Flowchart of estimation method for lifetime health expenditure per case of a specific type of cancer. Data were
obtained from the National Cancer Registry and National Mortality Registry to calculate the survival function and 
extrapolate to lifetime by the Monte Carlo method, which were integrated with the annual (or monthly) average health
expenditure obtained from the reimbursement file of the National Health Insurance to estimate lifetime health expenditure.
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who had visited a healthcare facility during the
period 1999–2003. We removed the 8651 patients
from the 200,000-person database, and totaled the
health expenditure for that portion of the general
population that was free from major illness for the
period 1999–2003. The total remaining health
expenditure was 9,819,674,747 TWD, which was
divided by 5 (years) and 191,349 (= 200,000 –
8651 persons) to obtain the average annual health
expenditure per case, or 10,264 TWD.
Results
The percentage of patients who survived to the
end of the 15-year follow-up (the censoring rate),
i.e. to the end of 2004, according to cancer type,
ranged from 8% to 67% (mean, 36%). The life
expectancy after diagnosis for the 17 major can-
cer sites is summarized in the Table and Figure 2.
The Table also shows the average annual health
expenditure and the lifetime health expenditure
for the 17 major cancer sites, which were adjusted
by two annual discount rates and one medical
care inflation rate, and expressed in TWD. Cancers
of the liver and the gallbladder and extrahepatic
bile duct had, respectively, the largest (8541) and
smallest (609) number of new or incidence cases
in 2001. Cases of cancers of the breast and co-
lorectum were more prevalent in the year than
cases of liver cancer, because patients with these
cancers generally survive longer. Figure 3 shows
that cancers with a longer survival time place a
higher lifetime financial burden per case on the
NHI. For example, although the average annual
health expenditure per case for cancer of the
ovary, breast, and cervix uteri were lower than
that for many other types of cancer, the lifetime
health expenditure per case for these cancers was
generally higher than for others. Leukemia had
the highest average annual health expenditure
per case (207,000 TWD) as well as the highest
lifetime health expenditure per case (2,404,000
TWD). Breast cancer had the highest total lifetime
health expenditure (5046 million TWD) because
of the long life expectancy. Furthermore, colorec-
tal cancer had the second highest total lifetime
health expenditure (4995 million TWD) due to
its high incidence. In addition, when the chosen
discount rate and medical care inflation rate were
the same (3%), the estimated costs were the same
as those without adjustment for both rates.
0
5
10
15
20
25
Pa
nc
rea
s
Lu
ng
Liv
er
Es
op
ha
gu
s
Ga
llb
lad
de
r &
ex
tra
he
pa
tic
 bi
le 
du
ct
St
om
ac
h
Pr
os
ta
te
Co
lor
ec
tu
m
Or
al 
ca
vit
y
Ki
dn
ey
 &
 ot
he
r
ur
ina
ry 
or
ga
ns
Le
uk
em
ia
Bl
ad
de
r
Na
so
ph
ar
yn
x
Sk
in
Ov
ar
y
Ce
rvi
x u
ter
i
Br
ea
st
Cancer type
Li
fe
 e
xp
ec
ta
nc
y 
(y
r)
Figure 2. Life expectancy for the 17 different types of cancer.
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Discussion
Although we have estimated the lifetime health
expenditure to the NHI for major cancers, the 
validity and limitation of the estimations must
be addressed before conclusions can be drawn.
Extrapolation using the Monte Carlo method re-
quires assumptions about premature mortality9
and a stable survival ratio between the cancer 
cohort and the reference population.12 Should
these assumptions be unwarranted, the validity
of the study would be threatened. However, the
Monte Carlo method has been confirmed, in pre-
viously published studies with validity tests, to
possess good validity for extrapolating the life-
time survival of patients with serious conditions
and diseases, such as permanent occupational
disabilities,10 serious occupational injuries,18 and
acute myelogenous leukemia.19 Moreover, because
the lifetime extrapolation is based on previous
and current clinical experiences, such as the life
table of the general population, the actual survival
(and hence, the health expenditure) is usually
underestimated. This is because the active devel-
opment and adoption of newer technology for
cancer treatments extends the survival time. For
example, currently, integrated cancer screening is
being implemented more extensively in Taiwan;
hence, more patients with early cancers can be
detected and may survive longer as a result.20 Thus,
our estimate of the financial burdens of cancer
patients on the NHI may even be conservative.
Given the use of new technologies that may pro-
long survival, the estimates should be revised 
periodically to obtain figures on life expectancy
and health expenditure that are more accurate.
In order to improve the accuracy of estimates of
life expectancy and health expenditure, future
work should focus on the following two factors.
First, some prognostic factors, such as tumor stag-
ing and performance status21,22 of the cancer 
cohort, could be considered. The cancer cohort
could then be stratified to a sub-cohort accord-
ing to these factors. Second, although for com-
parison we calculated the average annual health
expenditure per case (10,264 TWD) for people of
the general population who did not have major
illnesses, our estimates based on the NHI reim-
bursement data could not be considered as purely
cancer-attributable medical costs. In order to over-
come the challenge, details of some potential con-
founders (for example, underlying or concomitant
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Figure 3. Annual and lifetime health expenditure per case for 17 different types of cancer.
diseases) could be considered to facilitate better
comparability of the cancer cohort and the ref-
erence population23 as well as to improve the 
accuracy of the estimates.
The method employed in our study used the
average annual costs for the estimation, which
counts the total number of prevalence cases in a
particular year as the denominator and assumed
that a patient suffering from a major cancer gen-
erally comes back to a clinic or hospital at least
once a year for cancer management or follow-up
checks, even after treatment has been completed.
There is probably no need to worry about this 
assumption for cancers with a short life expectancy
(say, less than 5 years) such as cancers of the liver,
lung and pancreas. However, the assumption may
not be valid for cancers with long life expectancy.
Nonetheless, since all types of cancer are consid-
ered to fall into the category of catastrophic illnesses
and all clinic or hospital visits related to cancer
are covered comprehensively by the NHI, the 
potential overestimation of annual medical costs
from under-counting the number of prevalence
cases might be low.
Because the financial burden on the NHI de-
pends not only on the survival function, but also
on the chosen discount and medical care inflation
rates, the estimation of the health expenditure for
cancers that have longer survivals, e.g. breast, cervix
uteri and ovary, is affected more sensitively by the
chosen rates than the estimation of the health ex-
penditure for other cancers. Technologic advance-
ments regarding the diagnosis and treatment of
cancer develop more quickly than for other prod-
ucts; hence, there are uncertainties associated
with the use of the annual change rate of the CPI,
which is based on average costs.17 Thus, the poli-
cymaker could conduct a sensitivity analysis to
determine how various discount rates and medical
care inflation rates may affect financial planning.
In accordance with welfare economics, the
ideal approach for estimating the value of health
improvements, such as the prevention of a specific
type of cancer, may be to consider how much
people are willing to pay.24,25 Although quantifying
the value of willingness to pay (WTP) is more 
acceptable for resource allocation, it is difficult
to measure, especially if one is asked to respond
to a state behind a veil of ignorance.26 An alter-
native approach is to measure the cost of illness
by counting the combination of indirect costs
(loss of earnings) and direct costs (medical ex-
penses), which is considered to be the lower bound
of WTP.24 This study only estimated the health
expenditure paid by the NHI. This underestimates
even the direct costs, because at least out-of-
pocket expenses, such as those for transportation
to and from the hospital and the hiring of addi-
tional persons for supportive care, are not included.
Nonetheless, our estimations of the health expen-
diture paid by the NHI could be helpful for the
NHI’s policy planning, especially for prevention
programs for different types of cancer.27
The total cost of cancer includes not only the
suffering of patients from premature mortality
and morbidity, but also the financial burdens on
the NHI of diagnosing and treating cancer. In the
study reported herein, we successfully estimated
the lifetime costs for 17 different types of cancer.
Our estimates will be useful for the future assess-
ment of cost-effectiveness for the comparison of
different policies on cancer control. For example,
hepatitis B virus (HBV) is a causal factor for he-
patocellular carcinoma. The costs of immuniza-
tion (say, HBV vaccine) and/or treatment of HBV
infection could therefore be compared with the
periodic sonographic and/or serum tumor maker
(say, α-fetoprotein) for hepatocellular carcinoma.
In addition, since effective prevention measures
may eliminate completely both the patient’s pre-
mature mortality and morbidity and the finan-
cial burdens on the NHI, future research should
also focus on preventive medicine, rather than
only on the development and adoption of new
technology for diagnosis and treatment. Cancers
with chronic morbidity should have higher pri-
ority with respect to the development of pre-
ventive medicine. For example, cancers of the
oral cavity and breast, which have longer periods
of morbidity and larger average annual health
Financial burden on National Health Insurance for cancer
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expenditure per case, should have a higher prior-
ity for prevention research and action than other
types of cancer. Furthermore, our estimates can
also be used by the NHI directly, as an overview
of the potential financial benefit if a specific type
of cancer (e.g. hepatocellular carcinoma) can be
prevented by implementing a prevention measure
such as immunization (say, HBV vaccine).
In conclusion, we have proposed and imple-
mented a feasible method of measuring the life-
time health expenditure or the financial burden
for cancer on the NHI, even with high censoring
rates (for example, the mean of 36% that we
found in our study). The results may be helpful
to public health researchers and policymakers.
The estimation of the financial burdens of cancer
patients, as well as other traditional measures of
the burden of cancer, e.g. incidence, prevalence,
mortality, and years of life lost, could be used to
establish public health goals, to assess the alloca-
tion of healthcare resources across disease cate-
gories, and to evaluate the potential costs and
benefits of public health interventions.3
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